Adam Sky, MD
Psychiatry · Saint Louis, MONPI 1346388667
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $893,564 of the $1,111,003 with a category attached, or 80.4%. 33 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 45.8% of the total. Among psychiatry clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,258 payments — averaging $492.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$509K
- Avanir Pharmaceuticals, Inc.$344K
- Otsuka America Pharmaceutical, Inc.$211K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$34K
- Sunovion Pharmaceuticals Inc.$3K
- AbbVie$2K
- plus $9K from 27 others
What the payments were for
- Consulting fees$41,7724%
- Speaking & faculty fees$893,56480%
- Travel & lodging$140,04113%
- Food & beverage$35,3783%
- Education$2480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 691 | $508,503 |
| Avanir Pharmaceuticals, Inc. | 393 | $344,354 |
| Otsuka America Pharmaceutical, Inc. | 427 | $210,802 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 98 | $33,968 |
| Sunovion Pharmaceuticals Inc. | 95 | $2,696 |
| AbbVie(2 entities) | 153 | $1,856 |
| Biogen | 12 | $1,704 |
| Alkermes, Inc. | 37 | $986 |
| Lundbeck LLC | 68 | $947 |
| Vanda Pharmaceuticals Inc. | 45 | $920 |
| Neurocrine Biosciences, Inc. | 51 | $895 |
| Johnson & Johnson | 46 | $738 |
| Acadia Pharmaceuticals Inc | 14 | $477 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $427 |
| Axsome Therapeutics, Inc. | 14 | $224 |
| E.r. Squibb & Sons, L.L.C. | 16 | $211 |
| Livanova USA, Inc. | 4 | $205 |
| Noven Therapeutics, LLC | 8 | $144 |
| Eisai Inc. | 10 | $129 |
| Tris Pharma Inc | 7 | $109 |
| Bausch Health US, LLC | 6 | $98 |
| Lilly USA, LLC | 5 | $97 |
| Neos Therapeutics, LP | 5 | $80 |
| Ironshore Pharmaceuticals Inc. | 4 | $79 |
| Supernus Pharmaceuticals, Inc. | 4 | $63 |
| Idorsia Pharmaceuticals US Inc | 4 | $57 |
| Corium, LLC | 3 | $56 |
| Merck | 3 | $54 |
| Neuronetics, Inc. | 2 | $35 |
| Indivior Inc. | 2 | $28 |
| Shire North American Group Inc | 2 | $27 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUEDEXTA$405,245
- AUSTEDO$201,976
- Austedo XR$176,279
- REXULTI$139,818
- UZEDY$119,984
- CAPLYTA$32,545
- ADUHELM$1,480
- LATUDA$1,069
- ARISTADA$823
- LYBALVI$400
- VRAYLAR$345
- ARISTADA INITIO$206
- VNS Therapy Symmetry Model 8103 Generator$140
- INGREZZA$125
- LONHALA MAGNAIR$118
- NUPLAZID$100
How this compares
$1,111,003 in reported general payments places this provider in the 95th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 42 | $301,454 |
| AustedoDeutetrabenazine | 26 | $185,177 |
| Austedo XrDeutetrabenazine | 12 | $99,182 |
| RexultiBrexpiprazole | 88 | $75,294 |
| VraylarCariprazine Hcl | 50 | $71,201 |
| FanaptIloperidone | 34 | $50,913 |
| Invega SustennaPaliperidone Palmitate | 19 | $46,860 |
| NuedextaDextromethorphan Hbr/Quinidine | 45 | $43,095 |
| Risperdal ConstaRisperidone Microspheres | 21 | $26,692 |
| FetzimaLevomilnacipran Hcl | 27 | $17,056 |
| Olanzapine | 242 | $6,271 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 50 | $6,219 |
| Lisdexamfetamine Dimesylate | 20 | $6,068 |
| Aripiprazole | 68 | $5,911 |
| Quetiapine Fumarate | 391 | $5,426 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $895 | $301,45442 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $508,503 | $284,35838 claims |
| AbbVieVraylar, Fetzima | $1,856 | $88,25677 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $210,802 | $75,29488 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $738 | $73,55240 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $920 | $50,91334 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $344,354 | $43,09545 claims |
| Lilly USA, LLCOlanzapine | $97 | $6,271242 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $427 | $4,60812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Saint Louis
- Vadim BaramSaint Louis$1.9M
- Mohd MalikSaint Louis$956K
- George GrossbergSaint Louis$501K
- Christopher LoyndSaint Louis$265K
- Devnandini RastogiSaint Louis$261K
- Michael StotlerSaint Louis$250K
- James ChoSaint Louis$118K
- Steven HarveySaint Louis$90K
- Kevin BlackSaint Louis$77K
- Eric LenzeSaint Louis$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.